• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

IDH-305 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754979

IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor. IDH-305 shows greater than 200 fold selectivity for mutant IDH1 isoforms vs. WT (IC50s: 27nM (IDH1R132H), 28nM (IDH1R132C), 6.14uM (IDH1WT)). More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
IDH-305, Inhibitor
Full Product Name
IDH-305
Product Gene Name
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
490.45
Solubility
DMSO: 150mg/mL (305.84mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C23H22F4N6O2
SMILES
O=C1OC[C@H]([C@@H](F)C)N1C2=NC(N[C@H](C3=CC(C)=C(C4=CC(C(F)(F)F)=NC=C4)C=N3)C)=NC=C2
CAS Number
1628805-46-8
Target & IC50
IDH1R132H: ic50 27nM
IDH1R132C: ic50 28nM
IDH1WT: ic50 6.14uM
In Vitro
IDH-305 (30-300mg/kg; p.o.; twice daily for 21 days) suppresses 2-HG production and 2-HG-dependent tumor growth of an IDH1 mutant PDX melanoma model[1].

Structure of IDH-305, inhibitor

IDH-305 Inhibitor – Cat# MBS5754979

Product References and Citations for IDH-305, inhibitor

Cho YS, et al. Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Med Chem Lett. 2017 Sep 18;8(10):1116-1121.
Cho YS, et al. Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Med Chem Lett. 2017 Sep 18;8(10):1116-1121.
Courtney D DiNardo, et al. A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations. Blood, 128(22), 1073.
Courtney D DiNardo, et al. A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations. Blood, 128(22), 1073.

Other Notes

Small volumes of IDH-305, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for IDH-305 purchase

MBS5754979 is an inhibitor targeting IDH-305.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000